Ionis Pharmaceuticals Stock Analysis
IONS Stock | USD 35.46 1.45 4.26% |
Ionis Pharmaceuticals is undervalued with Real Value of 42.06 and Target Price of 51.15. The main objective of Ionis Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Ionis Pharmaceuticals is worth, separate from its market price. There are two main types of Ionis Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Ionis Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Ionis Pharmaceuticals is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Ionis Stock trading window is adjusted to America/New York timezone.
Ionis |
Ionis Stock Analysis Notes
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 101.16. Ionis Pharmaceuticals recorded a loss per share of 2.44. The entity had not issued any dividends in recent years. Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Ionis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 660 people. To learn more about Ionis Pharmaceuticals call Stanley Crooke at 760 931 9200 or check out https://www.ionispharma.com.Ionis Pharmaceuticals Investment Alerts
Ionis Pharmaceuticals generated a negative expected return over the last 90 days | |
The company reported the previous year's revenue of 787.65 M. Net Loss for the year was (366.29 M) with loss before overhead, payroll, taxes, and interest of (257.87 M). | |
Ionis Pharmaceuticals currently holds about 2.04 B in cash with (307.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.36. | |
Ionis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Over 99.0% of the company shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: Lou Gehrigs Disease Pipeline Landscape Report 2024 Therapeutic Assessment of 80 Drugs by Product Type, Stage, Route of Administration, and Molecule Type |
Ionis Pharmaceuticals Upcoming and Recent Events
28th of February 2024 Upcoming Quarterly Report | View | |
1st of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
28th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Ionis Largest EPS Surprises
Earnings surprises can significantly impact Ionis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2018-02-27 | 2017-12-31 | 0.01 | 0.02 | 0.01 | 100 | ||
2013-05-07 | 2013-03-31 | -0.02 | -0.03 | -0.01 | 50 | ||
2009-08-06 | 2009-06-30 | -0.02 | -0.03 | -0.01 | 50 |
Ionis Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Ionis Pharmaceuticals' ESG score is a quantitative measure that evaluates Ionis Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Ionis Pharmaceuticals' operations that may have significant financial implications and affect Ionis Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Ionis Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Pictet Asset Manangement Sa | 2024-06-30 | 2.4 M | Orbimed Advisors, Llc | 2024-06-30 | 2.4 M | Artisan Partners Limited Partnership | 2024-09-30 | 2.2 M | Deep Track Capital, Lp | 2024-09-30 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2 M | Macquarie Group Ltd | 2024-06-30 | 1.9 M | Clearbridge Advisors, Llc | 2024-09-30 | 1.7 M | Bvf Inc | 2024-09-30 | 1.5 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Fmr Inc | 2024-09-30 | 22.5 M | Vanguard Group Inc | 2024-09-30 | 15.1 M |
Ionis Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.37 B.Ionis Profitablity
The company has Profit Margin (PM) of (0.45) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.11.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.12) | (0.13) | |
Return On Capital Employed | (0.14) | (0.15) | |
Return On Assets | (0.12) | (0.13) | |
Return On Equity | (0.95) | (0.99) |
Management Efficiency
Ionis Pharmaceuticals has return on total asset (ROA) of (0.0725) % which means that it has lost $0.0725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7338) %, meaning that it created substantial loss on money invested by shareholders. Ionis Pharmaceuticals' management efficiency ratios could be used to measure how well Ionis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.13 in 2024. Return On Capital Employed is likely to drop to -0.15 in 2024. At this time, Ionis Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 365.6 M in 2024, whereas Intangible Assets are likely to drop slightly above 24.2 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.70 | 2.22 | |
Tangible Book Value Per Share | 2.70 | 1.97 | |
Enterprise Value Over EBITDA | (36.08) | (37.88) | |
Price Book Value Ratio | 18.73 | 17.80 | |
Enterprise Value Multiple | (36.08) | (37.88) | |
Price Fair Value | 18.73 | 17.80 | |
Enterprise Value | 7.5 B | 7.8 B |
Leadership effectiveness at Ionis Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Operating Margin (1.11) | Profit Margin (0.45) | Beta 0.392 | Return On Assets (0.07) | Return On Equity (0.73) |
Technical Drivers
As of the 25th of November, Ionis Pharmaceuticals retains the Risk Adjusted Performance of (0.13), market risk adjusted performance of (0.53), and Standard Deviation of 2.63. Ionis Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Ionis Pharmaceuticals variance and skewness to decide if Ionis Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 35.46 per share. Given that Ionis Pharmaceuticals has information ratio of (0.23), we strongly advise you to confirm Ionis Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.Ionis Pharmaceuticals Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ionis Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ionis Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Ionis Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ionis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ionis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ionis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ionis Pharmaceuticals Outstanding Bonds
Ionis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ionis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ionis bonds can be classified according to their maturity, which is the date when Ionis Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
US462222AB68 Corp BondUS462222AB68 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Ionis Pharmaceuticals Predictive Daily Indicators
Ionis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ionis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ionis Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 1st of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 12th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10th of September 2024 Other Reports | ViewVerify | |
9th of September 2024 Other Reports | ViewVerify |
Ionis Pharmaceuticals Forecast Models
Ionis Pharmaceuticals' time-series forecasting models are one of many Ionis Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ionis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Ionis Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Ionis Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ionis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ionis Pharmaceuticals. By using and applying Ionis Stock analysis, traders can create a robust methodology for identifying Ionis entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.42) | (0.45) | |
Operating Profit Margin | (0.45) | (0.47) | |
Net Loss | (0.47) | (0.49) | |
Gross Profit Margin | 0.99 | 1.04 |
Current Ionis Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ionis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ionis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
51.15 | Strong Buy | 25 | Odds |
Most Ionis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ionis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ionis Pharmaceuticals, talking to its executives and customers, or listening to Ionis conference calls.
Ionis Stock Analysis Indicators
Ionis Pharmaceuticals stock analysis indicators help investors evaluate how Ionis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ionis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Ionis Pharmaceuticals stock analysis, traders can identify Ionis Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 276.5 M | |
Long Term Debt | 1.2 B | |
Common Stock Shares Outstanding | 143.2 M | |
Total Stockholder Equity | 386.7 M | |
Tax Provision | 32.3 M | |
Quarterly Earnings Growth Y O Y | -0.437 | |
Property Plant And Equipment Net | 242.9 M | |
Cash And Short Term Investments | 2.3 B | |
Cash | 399.3 M | |
Accounts Payable | 26 M | |
Net Debt | 1.1 B | |
50 Day M A | 38.7056 | |
Total Current Liabilities | 448.1 M | |
Other Operating Expenses | 1.1 B | |
Non Current Assets Total | 348.2 M | |
Forward Price Earnings | 90.9091 | |
Non Currrent Assets Other | 62.3 M | |
Stock Based Compensation | 105.8 M |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.